- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01616537
Evaluation of Patient Satisfaction With and Acceptance of Their Totally-implanted Central Venous Catheter (QASICC-EVA)
Evaluation of Patient Satisfaction With and Acceptance of Their Totally-implanted Central Venous Catheter: Confirmatory Validation of QASICC Questionnaire
Background Patient satisfaction with or acceptance of care assessment is increasingly taken into account in oncology. Most cancer and other critically-ill patients require a totally-implanted Central Venous Catheter (CVC) for their treatment consisting of a reservoir connected to a central venous catheter, which may or may not be valved. It is impossible to estimate the number of CVC used in oncology. However, some authors claim that, in 2005, over 7 million CVCs were placed in the United States in both chronic and acute care. Although many patients fitted with a CVC are able to undertake activities which are hindered with other external vascular access devices, they are often physically or psychologically anxious about their device. To our knowledge, no validated questionnaire measuring patient acceptance of and satisfaction with their CVC has been reported in the literature. Based on these observations, the aim of our study was to develop and to validate a French-language questionnaire dubbed QASICC (Questionnaire for Acceptance of and Satisfaction with Implanted Central Venous Catheter) assessing patient satisfaction with and acceptance of their CVC. QASICC is designed as a multi-dimensional, self-administered questionnaire comprising approximately 30 items related to the use, appearance and pros and cons of the device as well as quality of life as perceived by patients using one for treatment.
Objective The purpose of the study is to validate a French-language self-administered questionnaire (QASICC) designed to evaluate patients' satisfaction and acceptance concerning their totally-implanted central venous catheter: confirmatory validation of questionnaire psychometric properties.
Study Design This is a prospective, multicenter, open study.
Primary Outcome Measures:
Questionnaire's 27 items tested on 990 patients to confirm QASICC internal structure:
- Items quality
- Dimensional structure
- Dimensional consistence
- Measure accuracy
- Measure reliability
- Sensitivity to change
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
QASICC Questionnaire The QASICC questionnaire included 27 questions (Q) assessing seven dimensions: pain during placement or use (Q1, Q2), contribution to the comfort of the treatment (Q3, Q4, Q7, Q10, Q12), esthetics and privacy (Q5, Q6, Q8, Q11, Q17, Q19), the impact on professional activities, social and sports (Q9, Q13, Q14, Q18, Q20), the impact on daily activities (Q15, Q16, Q21, Q22 ), local discomfort (Q23, Q24, Q25, Q26) and overall satisfaction (Q27). The device-related answers were of two types: Likert or visual analogue scale. Four types of Likert response were available: "no", "low," "moderate," "significant,"/"never," "sometimes," "often," "always "/" very easy "," easy "," difficult "," very difficult "/" not at all "," somewhat "," a lot "," extremely ". These questions are scored 0, 33, 67, 100, respectively, when the scores are correlated with symptoms, or 100, 67, 33, 0 when the scores are inversely correlated with symptoms. Visual analog scales (VAS) have a length of 100 mm. The score represents the number of mm measured on the scale. A mean score of acceptance and satisfaction can be calculated on a scale of 0 to 100 for all seven dimensions using the following formula: {(100-score DO) + CO + score (score ES-100) + (100-PR score) + (100-ES score) + (score 100-IN) + SA score} / 7. The higher the overall score, the greater the acceptance and satisfaction
The questionnaire is administered to the patient 30 days (+/-7 days) after CVC implantation.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Angers, France, 49933
- Centre Paul Papin - Ico
-
Caen, France, 14076
- Centre Francois Baclesse
-
Marseille, France, 13000
- CHU La Timone
-
Montpellier, France, 34295
- CHU de Montpellier
-
Nice, France, 06189
- Centre Antoine Lacassagne
-
Reims, France, 51056
- Institut Jean Godinot
-
Saint Cloud, France, 92210
- Centre René Huguenin
-
Strasbourg, France, 67065
- Centre Paul Strauss
-
Toulouse, France, 31052
- Institut Claudius Regaud
-
Vandoeuvre Les Nancy, France, 54511
- Centre Alexis Vautrin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years and older
- Patient who benefited or will benefit from the implantation of a CVC
- Solid tumor or hematologic malignancy
- WHO Performance Status 0-2
Exclusion Criteria:
- Any severe psychopathological disorder preventing completion of the questionnaire or invalidating questionnaire's measures
- Severe depressive state
- Non malignant pathology
- Inability to respond to questionnaires
- Patient not speaking fluent French
- Patient unable to consent
- Patient under guardianship
Study Plan
How is the study designed?
Design Details
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
QASICC questionnaire's 27 items tested on 990 patients to confirm the internal structure
Time Frame: 30 days (+/- 7 days) after CVC implantation
|
|
30 days (+/- 7 days) after CVC implantation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Questionnaire's 27 items tested on 990 patients to confirm QASICC external structure: convergent-divergent validity compared to EORTC-QLQC30 questionnaire.
Time Frame: 30 days (+/-7 days) after CVC implantation
|
convergent-divergent validity of the QASICC questionnaire compared to EORTC-QLQC30 questionnaire
|
30 days (+/-7 days) after CVC implantation
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: PIERRE YVES MARCY, MD, Centre Antoine Lacassagne
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2011-A01063-38
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Mast Cell Tumors
-
FSD Pharma, Inc.TerminatedMast Cell Activation Syndrome | Mast Cell Activation Disorder IdiopathicCanada, United States
-
Blueprint Medicines CorporationCompletedMast Cell Leukemia | Aggressive Systemic Mastocytosis | Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease | Relapsed or Refractory Myeloid MalignanciesUnited States, United Kingdom
-
Imagine InstituteNot yet recruiting
-
Blueprint Medicines CorporationCompletedSystemic Mast Cell Activation | KIT D816V MutationUnited States, France, United Kingdom, Italy, Germany, Belgium, Spain, Switzerland
-
Jason Robert GotlibNational Cancer Institute (NCI)TerminatedSystemic Mastocytosis | Mast Cell Leukemia | Aggressive Systemic MastocytosisUnited States
-
Blueprint Medicines CorporationRecruitingIndolent Systemic Mastocytosis | Monoclonal Mast Cell Activation SyndromeUnited States, Spain, Australia, France, Netherlands, Switzerland, Norway, United Kingdom, Austria, Belgium, Germany, Italy, Portugal
-
Blueprint Medicines CorporationActive, not recruitingMast Cell Leukemia | Aggressive Systemic Mastocytosis | Advanced Systemic Mastocytosis | Systemic Mastocytosis With an Associated Hematologic NeoplasmUnited States, Canada, United Kingdom, France, Netherlands, Italy, Spain, Austria, Denmark, Germany, Norway, Poland
-
Poitiers University HospitalCompletedMast Cell Activation Syndrome | Urticaria Pigmentosa | Mast Cell Activation Disease | Mast Cell DiseaseFrance
-
Jason Robert GotlibSeagen Inc.CompletedSystemic Mastocytosis | Mast Cell Leukemia | Aggressive Systemic MastocytosisUnited States
-
Adelphi Values LLCBlueprint Medicines CorporationCompletedMast Cell Leukemia (MCL) | Aggressive Systemic Mastocytosis (ASM) | SM w Assoc Clonal Hema Non-mast Cell Lineage Disease (SM-AHNMD) | Smoldering Systemic Mastocytosis (SSM) | Indolent Systemic Mastocytosis (ISM) ISM Subgroup Fully RecruitedUnited States
Clinical Trials on QUALITY OF LIFE QUESTIONNAIRE
-
University Hospital, MontpellierPediatric and Congenital Cardiology Department of Necker-enfant malades University...CompletedQuality of Life Assessment of Children With Congenital Heart Disease Aged 5 to 7 Years (QoL-CHD-5-7)Congenital Heart DiseaseFrance
-
City of Hope Medical CenterNational Cancer Institute (NCI)Recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | COVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Neuropathy | COVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingCervical Carcinoma | Endometrial Carcinoma | Vaginal Carcinoma | Malignant Female Reproductive System Neoplasm | Vulvar CarcinomaUnited States
-
Southwest Oncology GroupNational Cancer Institute (NCI)CompletedStage IVA Colon Cancer | Stage IVA Rectal Cancer | Stage IVB Colon Cancer | Stage IVB Rectal CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMalignant NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedCaregiver Burden, Quality of Life, and Symptom Distress at Different Palliative Cancer Care SettingsMetastatic Malignant Neoplasm | Advanced Malignant Neoplasm | Recurrent Malignant Neoplasm | Locally Advanced Malignant NeoplasmUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol Specific | Hematopoietic/Lymphoid CancerUnited States
-
University of ChicagoNational Cancer Institute (NCI)TerminatedTongue Cancer | Stage I Squamous Cell Carcinoma of the Oropharynx | Stage II Squamous Cell Carcinoma of the Oropharynx | Stage III Squamous Cell Carcinoma of the Oropharynx | Stage IVA Squamous Cell Carcinoma of the OropharynxUnited States